Updates

Findel

April 2013

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Findel has agreed to sell its NRS healthcare business for £24m, which will accelerate debt reduction plans and potentially also allow it to increase the securitisation facility for the Express Gifts' catalogue operations, which has historically circumscribed its ability to grow. Shareholder approval of the deal together with a resolution to consolidate the shares on a 20-for-1 basis is being sought at an EGM on 16 April. The sale of NRS dilutes forecast eps by around 10% for the year starting 1 April to 1.1p, with 1.3p next year.Separately, Findel has reported that sales growth at Express Gifts was 14.3% in the year to date although growth has eased in recent weeks as comparables become stronger. Despite a programme of reduc ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Tribal Group - International sales climb sharply

Advanced Computer Software - Buys Computer Software for Â£110m

Findel - Soon-to-be-prospective PE of just 7.9 (March 2015)

Findel (January 2014)

Findel - Highly geared for the long haul (September 2013)

Findel - Express Gifts momentum continues (July 2013)

Findel (February 2013)

Findel - Shares spike up on institutional buying (January 2013)

Findel (December 2012)

Findel -Prospective PE of 6.2 (November 2012)

Findel (May 2010)

Findel (February 2010)

Findel (October 2009)

Findel - PE of 7.7 versus sector average of 14 (September 2009)

Findel - Forecast upgraded following GLS acquisition (January 2005)

Findel - No loss of momentum on either side (June 2004)

Findel - Subprime recurring revenues (July 2002)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X